Please login to the form below

Not currently logged in
Email:
Password:

XLH

This page shows the latest XLH news and features for those working in and with pharma, biotech and healthcare.

NICE U-turn on Crystiva for rare bone disease

NICE U-turn on Crystiva for rare bone disease

NICE U-turn on Crystiva for rare bone disease. Set to back the drug to treat young people with XLH. ... This marks a step change in treatment for XLH, emphasised through the emotional testimonies provided by patient groups and clinicians following the

Latest news

  • NICE set to reject Kyowa Kirin’s Crysvita for XLH NICE set to reject Kyowa Kirin’s Crysvita for XLH

    NICE set to reject Kyowa Kirin’ s Crysvita for XLH. Committee says the rare disease therapy isn’t value for money. ... there is no treatment which targets the underlying pathophysiology of XLH – until now.

  • Rigel and Ultragenyx claim approvals for rare drugs Rigel and Ultragenyx claim approvals for rare drugs

    Rigel and Ultragenyx claim approvals for rare drugs. Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. ... Ultragenyx’s FDA approval was for Crysvita (burosumab), which has become the first approved drug for

  • Archive listing

    Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. .

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...

Infographics